Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Running, not enrolling · Phase 3

Conditions studied: Non-Small Cell Lung Cancer

In brief

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).

Key facts

Study ID
NCT05089734
Run by
Gilead Sciences
People needed
603
Starts
2021-11-17
Expected to finish
2027-01-01
Last updated by the study team
2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.